Resistance to multiple fluoroquinolones in a clinical isolate of Streptococcus pyogenes:: Identification of gyrA and parC and specification of point mutations associated with resistance

被引：59
作者：
Yan, SS
Fox, ML
Holland, SM
Stock, F
Gill, VJ
Fedorko, DP
机构：
[1] NIAID, Microbiol Serv, CPD, Ctr Clin,NIH, Bethesda, MD 20892 USA
[2] NIAID, Host Def Lab, NIH, Bethesda, MD 20892 USA
来源：
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY | 2000年 / 44卷 / 11期
关键词：
D O I：
10.1128/AAC.44.11.3196-3198.2000
中图分类号：
Q93 [微生物学];
学科分类号：
071005 ; 100705 ;
摘要：
A strain of Streptococcus pyogenes resistant to multiple fluoroquinolones was isolated from the blood of an immunocompromised patient. Resistance to fluoroquinolones in S. pyogenes has not been previously studied. Compared to 10 sensitive strains of S. pyogenes, the fluoroquinolone-resistant clinical isolate of S, pyogenes presented point mutations in gyrA, predicting that serine-81 was changed to phenylalanine and that methionine-99 was changed to leucine, and in parC, predicting that serine-79 was changed to tyrosine. The mechanism of fluoroquinolone resistance in this isolate of S. pyogenes appears to be analogous to previously reported mechanisms for Streptococcus pneumoniae.
引用
收藏
页码：3196 / 3198
页数：3
相关论文
共 18 条
[11]   ParC subunit of DNA topoisomerase IV of Streptococcus pneumoniae is a primary target of fluoroquinolones and cooperates with DNA gyrase A subunit in forming resistance phenotype [J].
Munoz, R ;
DelaCampa, AG .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1996, 40 (10) :2252-2257
[12]   DNA gyrase and topoisomerase IV are dual targets of clinafloxacin action in Streptococcus pneumoniae [J].
Pan, XS ;
Fisher, LM .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1998, 42 (11) :2810-2816
[13]   Targeting of DNA gyrase in Streptococcus pneumoniae by sparfloxacin: Selective targeting of gyrase or topoisomerase IV by quinolones [J].
Pan, XS ;
Fisher, LM .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1997, 41 (02) :471-474
[14]   Involvement of topoisomerase IV and DNA gyrase as ciprofloxacin targets in Streptococcus pneumoniae [J].
Pan, XS ;
Ambler, J ;
Mehtar, S ;
Fisher, LM .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1996, 40 (10) :2321-2326
[15]   INVASIVE GROUP A STREPTOCOCCUS INFECTIONS [J].
STEVENS, DL .
CLINICAL INFECTIOUS DISEASES, 1992, 14 (01) :2-13
[16]   Contribution of mutations in gyrA and parC genes to fluoroquinolone resistance of mutants of Streptococcus pneumoniae obtained in vivo and in vitro [J].
Tankovic, J ;
Perichon, B ;
Duval, J ;
Courvalin, P .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1996, 40 (11) :2505-2510
[17]   Comparative in vitro activities of four new fluoroquinolones against Streptococcus pneumoniae determined by Etest [J].
Waites, K ;
Brookings, E ;
Nix, S ;
Robinson, A ;
Gray, B ;
Swiatlo, E .
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 1998, 9 (04) :215-218
[18]   QUINOLONE RESISTANCE-DETERMINING REGION IN THE DNA GYRASE GYRA GENE OF ESCHERICHIA-COLI [J].
YOSHIDA, H ;
BOGAKI, M ;
NAKAMURA, M ;
NAKAMURA, S .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1990, 34 (06) :1271-1272
12